Zilebesiran REVERSIR: A Generalizable Platform to Restore Activity of Target mRNA

- Although clinical data do not indicate the need for a reversal agent,[1,2] the long-acting nature of zilebesiran has prompted questions on how short-term reversal may be managed[3]
- Zilebesiran REVERSIR (RVR) is a reverse siRNA silencing technology that is being researched to counteract siRNA-mediated pharmacodynamic effects[4]
- **Therapeutic Hypothesis:** The RVR molecule targets siRNAs so that their recognition and silencing of mRNA is blocked, and protein production may resume[4]

Zilebesiran REVERSIR is under investigation in the setting of hypertension

mRNA, messenger ribonucleic acid; RVR, REVERSIR; siRNA, small interfering ribonucleic acid. 1. Bakris GL et al. JAMA. 2024;331(9):740–9. 2. Bakris GL et al. American College of Cardiology Annual Scientific Session & Expo, April 6–8, 2024, Atlanta, GA, USA. Oral presentation. 3. Touyz RM. N Engl J Med. 2023;389(3):278–81. 4. Ye D et al. Hypertension. 2024;81(7):1491–9.

Alnylam